Beyond the monoamines: The future of antidepressants

August 16, 2018|Internal Medicine

Dr. Aaronson is the director of clinical research programs at the Sheppard Pratt Health System in Baltimore. He serves as a consultant to several companies, including Alkermes, Genomind, LivaNova, Neuronetics, and Sage Therapeutics. He has received honoraria for speaking from Neurocrine, Otsuka, and Sunovion. He has received research support from Neuronetics. Dr. Aaronson also serves as a clinical associate professor of psychiatry at the University of Maryland, Baltimore, and is a Distinguished Fellow of the American Psychiatric Association and a Fellow of the American College of Psychiatrists.

References

1. Am J Psychiatry. 2006;163(11):1905-17.

2. JAMA Psychiatry. 2018 Feb 1;75(2):139-48.

3. Am J Psychiatry. 2018 Jul 1;175(7):620-30.

4. JAMA Psychiatry. 2017;74(4):399-405.

5. Am J Psychiatry. 2016 May 1;173(5):499-508.

6. Lancet. 2017 Jul 29;390(10093):480-9.

7. J Psychopharmacol. 2016;30(12):1181-97.

8. Psychopharmacology (Berl). 2018 Feb;235(2):399-408.

9. Sci Rep. 2017 Oct 13;7(1):13187.

*Correction, 10/18/2019: An earlier version of this story misidentified buprenorphine.